MX369025B - Inhibidores de aldosterona sintasa. - Google Patents

Inhibidores de aldosterona sintasa.

Info

Publication number
MX369025B
MX369025B MX2017004852A MX2017004852A MX369025B MX 369025 B MX369025 B MX 369025B MX 2017004852 A MX2017004852 A MX 2017004852A MX 2017004852 A MX2017004852 A MX 2017004852A MX 369025 B MX369025 B MX 369025B
Authority
MX
Mexico
Prior art keywords
compounds
synthase inhibitors
aldosterone synthase
processes
relates
Prior art date
Application number
MX2017004852A
Other languages
English (en)
Spanish (es)
Other versions
MX2017004852A (es
Inventor
Surprenant Simon
R Hornberger Keith
Michael MEYERS Kenneth
Allen Nemoto Peter
Yu Hui
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54352516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369025(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2017004852A publication Critical patent/MX2017004852A/es
Publication of MX369025B publication Critical patent/MX369025B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2017004852A 2014-10-15 2015-10-14 Inhibidores de aldosterona sintasa. MX369025B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064234P 2014-10-15 2014-10-15
PCT/US2015/055421 WO2016061161A1 (en) 2014-10-15 2015-10-14 Aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
MX2017004852A MX2017004852A (es) 2017-06-22
MX369025B true MX369025B (es) 2019-10-25

Family

ID=54352516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004852A MX369025B (es) 2014-10-15 2015-10-14 Inhibidores de aldosterona sintasa.

Country Status (33)

Country Link
US (1) US9745289B2 (enExample)
EP (1) EP3207039B1 (enExample)
JP (1) JP6279812B2 (enExample)
KR (1) KR102441634B1 (enExample)
CN (1) CN107108587B (enExample)
AP (1) AP2017009829A0 (enExample)
AR (1) AR102266A1 (enExample)
AU (1) AU2015333611B2 (enExample)
CA (1) CA2964754C (enExample)
CL (1) CL2017000827A1 (enExample)
CO (1) CO2017003305A2 (enExample)
CY (1) CY1121650T1 (enExample)
DK (1) DK3207039T3 (enExample)
EA (1) EA031766B1 (enExample)
ES (1) ES2724555T3 (enExample)
HR (1) HRP20190896T1 (enExample)
HU (1) HUE043783T2 (enExample)
IL (1) IL251200B (enExample)
LT (1) LT3207039T (enExample)
ME (1) ME03381B (enExample)
MX (1) MX369025B (enExample)
NZ (1) NZ729688A (enExample)
PE (1) PE20170696A1 (enExample)
PH (1) PH12017500595B1 (enExample)
PL (1) PL3207039T3 (enExample)
PT (1) PT3207039T (enExample)
RS (1) RS58651B1 (enExample)
SG (1) SG11201701850UA (enExample)
SI (1) SI3207039T1 (enExample)
TR (1) TR201907755T4 (enExample)
TW (1) TWI731842B (enExample)
UA (1) UA118717C2 (enExample)
WO (1) WO2016061161A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089800A1 (en) * 2014-12-02 2016-06-09 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
CA3055292A1 (en) * 2016-12-29 2018-07-05 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN113767095A (zh) 2019-05-01 2021-12-07 勃林格殷格翰国际有限公司 (r)-4-溴苯磺酸(2-甲基环氧乙烷-2-基)甲酯
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
AU2022415313A1 (en) 2021-12-14 2024-05-02 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
CN121181527A (zh) * 2024-06-21 2025-12-23 江苏豪森药业集团有限公司 双稠环类化合物、及其制备方法和应用
WO2026093586A1 (en) 2024-11-04 2026-05-07 AstraZeneca Ireland Limited Combination of a aldosterone synthase inhibitor (asi) and a sodium-glucose co-transporter 2 inhibitor (sglt2i) for use in methods of reducing the risk of cardiovascular and heart failure events in a subject

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073629A1 (es) * 2008-10-07 2010-11-17 Schering Corp Analogos de benzodioxano moduladores de receptores adrenergicos alfa 2c, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias, alergicas, cardiacas, parkinson y/o alzheimer, entre otras
ES2459468T3 (es) * 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
MX350717B (es) * 2011-11-30 2017-09-14 Hoffmann La Roche Nuevos derivados biciclicos de dihidroisoquinolin-1-ona.
US9550750B2 (en) 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
JP2016516004A (ja) * 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
ES2684050T3 (es) * 2014-07-24 2018-10-01 Boehringer Ingelheim International Gmbh Inhibidores de aldosterona sintasa

Also Published As

Publication number Publication date
EP3207039B1 (en) 2019-03-06
PH12017500595B1 (en) 2020-11-25
WO2016061161A1 (en) 2016-04-21
JP6279812B2 (ja) 2018-02-14
AP2017009829A0 (en) 2017-03-31
HRP20190896T1 (hr) 2019-07-12
AU2015333611A1 (en) 2017-03-23
CY1121650T1 (el) 2020-07-31
PL3207039T3 (pl) 2019-08-30
AR102266A1 (es) 2017-02-15
CN107108587A (zh) 2017-08-29
NZ729688A (en) 2020-05-29
SG11201701850UA (en) 2017-04-27
TW201629048A (zh) 2016-08-16
TWI731842B (zh) 2021-07-01
CO2017003305A2 (es) 2017-07-19
UA118717C2 (uk) 2019-02-25
RS58651B1 (sr) 2019-05-31
EA201790830A1 (ru) 2017-09-29
SI3207039T1 (sl) 2019-05-31
LT3207039T (lt) 2019-05-10
KR20170066651A (ko) 2017-06-14
US20160108026A1 (en) 2016-04-21
JP2017531016A (ja) 2017-10-19
ME03381B (me) 2020-01-20
CA2964754A1 (en) 2016-04-21
TR201907755T4 (tr) 2019-06-21
HUE043783T2 (hu) 2019-09-30
MX2017004852A (es) 2017-06-22
PE20170696A1 (es) 2017-06-07
AU2015333611B2 (en) 2020-02-06
CL2017000827A1 (es) 2017-11-03
BR112017005859A2 (pt) 2017-12-26
EP3207039A1 (en) 2017-08-23
PH12017500595A1 (en) 2017-08-30
KR102441634B1 (ko) 2022-09-13
DK3207039T3 (en) 2019-04-23
ES2724555T3 (es) 2019-09-12
IL251200B (en) 2019-05-30
EA031766B1 (ru) 2019-02-28
IL251200A0 (en) 2017-05-29
US9745289B2 (en) 2017-08-29
CA2964754C (en) 2023-01-24
CN107108587B (zh) 2020-05-22
PT3207039T (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
PH12017500089A1 (en) Aldosterone synthase inhibitors
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
PH12017500595A1 (en) Aldosterone synthase inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
TW201613864A (en) Novel compounds
PH12016501462A1 (en) Neprilysin inhibitors
MD20170011A2 (ro) Compuşi imidazopiridazinici
MX2016009759A (es) Inhibidores de neprilisina.
IN2013DN02555A (enExample)
PH12016501764A1 (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production

Legal Events

Date Code Title Description
FG Grant or registration